Table 3 Asthma disease characteristics in the Ext-SLS cohort and SLS ITT populations, captured at entry to the SLS.
From: Extending the data collection from a clinical trial: The Extended Salford Lung Study research cohort
Ext-SLS Population (N = 798) | SLS ITT Population (N = 4233) | |
|---|---|---|
Duration of asthma, n (%)a | ||
<6 months | 10 (1.3) | 54 (1.3) |
≥6 months to <1 year | 11 (1.4) | 77 (1.8) |
≥1 to <5 years | 82 (10.3) | 438 (10.3) |
≥5 to <10 years | 97 (12.2) | 519 (12.3) |
≥10 years | 598 (74.9) | 3144 (74.3) |
Any daytime symptoms more than twice a week?, n (%) | ||
Yes | 708 (88.7) | 3830 (90.5) |
No | 90 (11.3) | 403 (9.5) |
Use of SABA more than twice a week?, n (%) | ||
Yes | 551 (69.0) | 3044 (71.9) |
No | 247 (31.0) | 1189 (28.1) |
Any limitations of activities in the past week?, n (%) | ||
Yes | 385 (48.2) | 2162 (51.1) |
No | 413 (51.8) | 2071 (48.9) |
Any nocturnal symptoms/awakening in past week?, n (%) | ||
Yes | 393 (49.2) | 2117 (50.0) |
No | 405 (50.8) | 2116 (50.0) |
Total number of exacerbations (any severity) in the year prior to randomization, n (%) | ||
0 | 513 (64.3) | 2692 (63.6) |
1 | 183 (22.9) | 973 (23.0) |
≥2 | 102 (12.8) | 568 (13.4) |
Mean (SD) | 0.6 (1.2) | 0.6 (1.1) |
Range | 0–12 | 0–14 |
Number of severe asthma exacerbations in year prior to randomization, n (%) | ||
0 | 513 (64.3) | 2692 (63.6) |
≥1 | 285 (35.7) | 1541 (36.4) |
ACT score, n (%) | ||
≥20 | 263 (33.0) | 1210 (28.6) |
16–19 | 250 (31.3) | 1307 (30.9) |
≤15 | 285 (35.7) | 1716 (40.5) |
Asthma symptoms, n (%) | ||
<2 questions answered yes | 141 (17.7) | 634 (15.0) |
≥2 questions answered yes | 657 (82.3) | 3599 (85.0) |
